Development of thiophenic analogues of benzothiadiazine dioxides as new powerful potentiators of 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid (AMPA) receptors. 2013

Pierre Francotte, and Eric Goffin, and Pierre Fraikin, and E Graindorge, and Pierre Lestage, and Laurence Danober, and Sylvie Challal, and Nathalie Rogez, and Olivier Nosjean, and Daniel-Henri Caignard, and Bernard Pirotte, and Pascal de Tullio
Centre Interfacultaire de Recherche du Médicament (CIRM)-Laboratoire de Chimie Pharmaceutique, University of Liege , Avenue de l'Hôpital 1, B36, 4000 Liège, Belgium.

On the basis of the results obtained in previous series of AMPA potentiators belonging to 3,4-dihydro-2H-benzo- and 3,4-dihydro-2H-pyrido-1,2,4-thiadiazine 1,1-dioxides, the present work focuses on the design of original isosteric 3,4-dihydro-2H-thieno-1,2,4-thiadiazine 1,1-dioxides. Owing to the sulfur position, three series of compounds were developed and their activity as AMPA potentiators was characterized. In each of the developed series, potent compounds were discovered. After screening the selected active compounds on a safety in vivo test, 6-chloro-4-ethyl-3,4-dihydro-2H-thieno[2,3-e]-1,2,4-thiadiazine 1,1-dioxide (24) appeared as the most promising compound and was further evaluated. Its effects on long-term potentiation in vivo and on AMPA-mediated noradrenaline release were measured to predict its potential cognitive enhancing properties. Finally, an object recognition test performed in mice revealed that 24 was able to significantly enhance cognition, after oral administration, at doses as low as 0.3 mg/kg. This study validates the interest of the isosteric replacement of the benzene or pyridine nuclei by the thiophene nucleus in the ring-fused thiadiazine dioxides class of AMPA potentiators.

UI MeSH Term Description Entries
D008564 Membrane Potentials The voltage differences across a membrane. For cellular membranes they are computed by subtracting the voltage measured outside the membrane from the voltage measured inside the membrane. They result from differences of inside versus outside concentration of potassium, sodium, chloride, and other ions across cells' or ORGANELLES membranes. For excitable cells, the resting membrane potentials range between -30 and -100 millivolts. Physical, chemical, or electrical stimuli can make a membrane potential more negative (hyperpolarization), or less negative (depolarization). Resting Potentials,Transmembrane Potentials,Delta Psi,Resting Membrane Potential,Transmembrane Electrical Potential Difference,Transmembrane Potential Difference,Difference, Transmembrane Potential,Differences, Transmembrane Potential,Membrane Potential,Membrane Potential, Resting,Membrane Potentials, Resting,Potential Difference, Transmembrane,Potential Differences, Transmembrane,Potential, Membrane,Potential, Resting,Potential, Transmembrane,Potentials, Membrane,Potentials, Resting,Potentials, Transmembrane,Resting Membrane Potentials,Resting Potential,Transmembrane Potential,Transmembrane Potential Differences
D008956 Models, Chemical Theoretical representations that simulate the behavior or activity of chemical processes or phenomena; includes the use of mathematical equations, computers, and other electronic equipment. Chemical Models,Chemical Model,Model, Chemical
D009638 Norepinephrine Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic. Levarterenol,Levonorepinephrine,Noradrenaline,Arterenol,Levonor,Levophed,Levophed Bitartrate,Noradrenaline Bitartrate,Noradrénaline tartrate renaudin,Norepinephrin d-Tartrate (1:1),Norepinephrine Bitartrate,Norepinephrine Hydrochloride,Norepinephrine Hydrochloride, (+)-Isomer,Norepinephrine Hydrochloride, (+,-)-Isomer,Norepinephrine d-Tartrate (1:1),Norepinephrine l-Tartrate (1:1),Norepinephrine l-Tartrate (1:1), (+,-)-Isomer,Norepinephrine l-Tartrate (1:1), Monohydrate,Norepinephrine l-Tartrate (1:1), Monohydrate, (+)-Isomer,Norepinephrine l-Tartrate (1:2),Norepinephrine l-Tartrate, (+)-Isomer,Norepinephrine, (+)-Isomer,Norepinephrine, (+,-)-Isomer
D009865 Oocytes Female germ cells derived from OOGONIA and termed OOCYTES when they enter MEIOSIS. The primary oocytes begin meiosis but are arrested at the diplotene state until OVULATION at PUBERTY to give rise to haploid secondary oocytes or ova (OVUM). Ovocytes,Oocyte,Ovocyte
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003071 Cognition Intellectual or mental process whereby an organism obtains knowledge. Cognitive Function,Cognitions,Cognitive Functions,Function, Cognitive,Functions, Cognitive
D003499 Cyclic S-Oxides Heterocyclic S-Oxides,Cyclic S Oxides,Heterocyclic S Oxides,Oxides, Cyclic S,S Oxides, Cyclic,S-Oxides, Cyclic,S-Oxides, Heterocyclic
D003981 Diazoxide A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group. Hyperstat,Proglycem
D005260 Female Females
D006624 Hippocampus A curved elevation of GRAY MATTER extending the entire length of the floor of the TEMPORAL HORN of the LATERAL VENTRICLE (see also TEMPORAL LOBE). The hippocampus proper, subiculum, and DENTATE GYRUS constitute the hippocampal formation. Sometimes authors include the ENTORHINAL CORTEX in the hippocampal formation. Ammon Horn,Cornu Ammonis,Hippocampal Formation,Subiculum,Ammon's Horn,Hippocampus Proper,Ammons Horn,Formation, Hippocampal,Formations, Hippocampal,Hippocampal Formations,Hippocampus Propers,Horn, Ammon,Horn, Ammon's,Proper, Hippocampus,Propers, Hippocampus,Subiculums

Related Publications

Pierre Francotte, and Eric Goffin, and Pierre Fraikin, and E Graindorge, and Pierre Lestage, and Laurence Danober, and Sylvie Challal, and Nathalie Rogez, and Olivier Nosjean, and Daniel-Henri Caignard, and Bernard Pirotte, and Pascal de Tullio
November 2000, Journal of medicinal chemistry,
Pierre Francotte, and Eric Goffin, and Pierre Fraikin, and E Graindorge, and Pierre Lestage, and Laurence Danober, and Sylvie Challal, and Nathalie Rogez, and Olivier Nosjean, and Daniel-Henri Caignard, and Bernard Pirotte, and Pascal de Tullio
August 1996, Journal of medicinal chemistry,
Pierre Francotte, and Eric Goffin, and Pierre Fraikin, and E Graindorge, and Pierre Lestage, and Laurence Danober, and Sylvie Challal, and Nathalie Rogez, and Olivier Nosjean, and Daniel-Henri Caignard, and Bernard Pirotte, and Pascal de Tullio
July 1995, Journal of receptor and signal transduction research,
Pierre Francotte, and Eric Goffin, and Pierre Fraikin, and E Graindorge, and Pierre Lestage, and Laurence Danober, and Sylvie Challal, and Nathalie Rogez, and Olivier Nosjean, and Daniel-Henri Caignard, and Bernard Pirotte, and Pascal de Tullio
September 2008, Acta pharmaceutica (Zagreb, Croatia),
Pierre Francotte, and Eric Goffin, and Pierre Fraikin, and E Graindorge, and Pierre Lestage, and Laurence Danober, and Sylvie Challal, and Nathalie Rogez, and Olivier Nosjean, and Daniel-Henri Caignard, and Bernard Pirotte, and Pascal de Tullio
July 1998, Journal of medicinal chemistry,
Pierre Francotte, and Eric Goffin, and Pierre Fraikin, and E Graindorge, and Pierre Lestage, and Laurence Danober, and Sylvie Challal, and Nathalie Rogez, and Olivier Nosjean, and Daniel-Henri Caignard, and Bernard Pirotte, and Pascal de Tullio
March 2016, Journal of medicinal chemistry,
Pierre Francotte, and Eric Goffin, and Pierre Fraikin, and E Graindorge, and Pierre Lestage, and Laurence Danober, and Sylvie Challal, and Nathalie Rogez, and Olivier Nosjean, and Daniel-Henri Caignard, and Bernard Pirotte, and Pascal de Tullio
May 2002, Journal of medicinal chemistry,
Pierre Francotte, and Eric Goffin, and Pierre Fraikin, and E Graindorge, and Pierre Lestage, and Laurence Danober, and Sylvie Challal, and Nathalie Rogez, and Olivier Nosjean, and Daniel-Henri Caignard, and Bernard Pirotte, and Pascal de Tullio
January 1997, Chirality,
Pierre Francotte, and Eric Goffin, and Pierre Fraikin, and E Graindorge, and Pierre Lestage, and Laurence Danober, and Sylvie Challal, and Nathalie Rogez, and Olivier Nosjean, and Daniel-Henri Caignard, and Bernard Pirotte, and Pascal de Tullio
November 2015, Journal of medicinal chemistry,
Pierre Francotte, and Eric Goffin, and Pierre Fraikin, and E Graindorge, and Pierre Lestage, and Laurence Danober, and Sylvie Challal, and Nathalie Rogez, and Olivier Nosjean, and Daniel-Henri Caignard, and Bernard Pirotte, and Pascal de Tullio
August 2008, Chemical & pharmaceutical bulletin,
Copied contents to your clipboard!